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A bs tr ac t
Background
Early-phase and preclinical studies suggest that moxifloxacin-containing regimens 
could allow for effective 4-month treatment of uncomplicated, smear-positive pul-
monary tuberculosis.
Methods
We conducted a randomized, double-blind, placebo-controlled, phase 3 trial to test 
the noninferiority of two moxifloxacin-containing regimens as compared with a 
control regimen. One group of patients received isoniazid, rifampin, pyrazinamide, 
and ethambutol for 8 weeks, followed by 18 weeks of isoniazid and rifampin (con-
trol group). In the second group, we replaced ethambutol with moxifloxacin for 17 
weeks, followed by 9 weeks of placebo (isoniazid group), and in the third group, we 
replaced isoniazid with moxifloxacin for 17 weeks, followed by 9 weeks of placebo 
(ethambutol group). The primary end point was treatment failure or relapse within 
18 months after randomization.
Results
Of the 1931 patients who underwent randomization, in the per-protocol analysis, a 
favorable outcome was reported in fewer patients in the isoniazid group (85%) and 
the ethambutol group (80%) than in the control group (92%), for a difference favor-
ing the control group of 6.1 percentage points (97.5% confidence interval [CI], 1.7 to 
10.5) versus the isoniazid group and 11.4 percentage points (97.5% CI, 6.7 to 16.1) 
versus the ethambutol group. Results were consistent in the modified intention-to-
treat analysis and all sensitivity analyses. The hazard ratios for the time to culture 
negativity in both solid and liquid mediums for the isoniazid and ethambutol 
groups, as compared with the control group, ranged from 1.17 to 1.25, indicating 
a shorter duration, with the lower bounds of the 95% confidence intervals exceed-
ing 1.00 in all cases. There was no significant difference in the incidence of grade 
3 or 4 adverse events, with events reported in 127 patients (19%) in the isoniazid 
group, 111 (17%) in the ethambutol group, and 123 (19%) in the control group.
Conclusions
The two moxifloxacin-containing regimens produced a more rapid initial decline in 
bacterial load, as compared with the control group. However, noninferiority for these 
regimens was not shown, which indicates that shortening treatment to 4 months 
was not effective in this setting. (Funded by the Global Alliance for TB Drug De-
velopment and others; REMoxTB ClinicalTrials.gov number, NCT00864383.)
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A short-term tuberculosis treat-ment regimen could improve rates of ad-herence, reduce rates of adverse events, and 
lower costs. Fluoroquinolones have shown prom-
ising activity against mycobacteria1 and are es-
tablished as a critical component of the treatment 
of multidrug-resistant tuberculosis,2,3 with later 
fluoroquinolones recognized as having a more po-
tent effect. It has been proposed that these drugs 
may have a role in reducing the duration of tuber-
culosis treatment.4
Moxifloxacin has been approved for a range 
of indications globally.5 It has favorable pharma-
cokinetics, a large volume of distribution, and 
penetration into epithelial-lining fluid and mac-
rophages.6-8 The activity of moxifloxacin in vitro 
against Mycobacterium tuberculosis, which has been 
confirmed in murine models9 and in clinical 
monotherapy studies,10,11 has raised the prospect 
that the drug could be used as part of an improved 
regimen.1 Subsequent studies in mice showed 
that combination regimens that included moxi-
floxacin had greater bactericidal activity than stan-
dard treatment and could produce cure without 
relapse after a shorter treatment duration.12,13
When different fluoroquinolones were substi-
tuted for ethambutol in a clinical trial, the moxi-
floxacin-containing regimen produced the most 
rapid decline in bacterial load and in the propor-
tion of patients with culture negativity at 8 weeks.14 
These findings were confirmed by investigators in 
Brazil.15 In contrast, substituting moxifloxacin for 
isoniazid in an 8-week study resulted in a non-
significant enhancement in bactericidal effect.16
On the basis of supportive evidence from 
phase 2 studies and the uncertain relationships 
between 8-week bacteriologic data and the du-
ration of effective therapy, we designed the Ra-
pid Evaluation of Moxifloxacin in Tuberculosis 
(REMoxTB) study to determine whether the re-
placement of either isoniazid or ethambutol with 
moxifloxacin would provide effective tuberculo-
sis treatment in 4 months, as compared with the 
standard 6-month regimen.
Me thods
Study Design and Oversight
REMoxTB was a placebo-controlled, randomized, 
double-blind, phase 3 trial to test the noninferi-
ority of two moxifloxacin-containing 4-month reg-
imens, as compared with the standard 6-month 
regimen (Fig. S1 in the Supplementary Appendix, 
available with the full text of this article at NEJM.
org). The full trial protocol and statistical analy-
sis plan are also available at NEJM.org.
A trial steering committee with an indepen-
dent chair supervised the conduct of the trial. An 
independent data and safety monitoring commit-
tee with access to unblinded data oversaw the 
safety of the study patients. The ethics commit-
tee at University College London and all national 
and local ethics committees approved the study. 
The Food and Drug Administration, the Federal 
Institute for Drugs and Medical Devices (Bundes-
institut für Arzneimittel und Medizinprodukte), 
and the national regulatory authorities of the 
countries in which the trial was conducted re-
viewed and approved the protocol.
Bayer Healthcare donated moxifloxacin, and 
Sanofi donated rifampin. Neither company had 
any role in the study design, data accrual, data 
analysis, or manuscript preparation. Representa-
tives of Bayer Healthcare reviewed the manuscript 
but did not suggest revisions. All the authors 
vouch for the completeness and accuracy of the 
data and analyses presented.
Study Patients
Patients were adults (≥18 years of age) who had 
newly diagnosed, previously untreated M. tubercu-
losis infection, as determined by positive results 
on sputum smears on two occasions, with cul-
ture-confirmed susceptibility to rifampin and fluo-
roquinolones. Patients who were coinfected with 
the human immunodeficiency virus (HIV) were 
eligible to participate in the study if the CD4+ 
count was at least 250 cells per cubic millimeter 
and they were not already receiving antiretroviral 
therapy. Detailed inclusion and exclusion criteria 
are provided in the Supplementary Appendix. All 
patients provided written or witnessed oral in-
formed consent.
Randomization and Study Treatments
Randomization was performed with the use of 
lists with blocks of variable sizes that were strat-
ified according to the patient weight group and 
study center. During randomization, patients were 
assigned a unique study number selected sequen-
tially from the appropriate randomization list that 
corresponded to the treatment pack allocated. Eli-
gible patients were assigned in a 1:1:1 ratio to one 
of the following daily regimens: a control regimen, 
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which consisted of isoniazid, rifampin, pyrazin-
amide, and ethambutol for 8 weeks, followed by 
18 weeks of isoniazid and rifampin (control group); 
a regimen in which we replaced ethambutol with 
moxifloxacin for 17 weeks, followed by 9 weeks 
of placebo (isoniazid group); and a regimen in 
which we replaced isoniazid with moxifloxacin 
for 17 weeks, followed by 9 weeks of placebo (eth-
ambutol group). Details about the regimens are 
provided in Figure S1 in the Supplementary Ap-
pendix.
In all three groups, drug doses were adjusted 
according to patient weight, as described in Ta-
ble S2 in the Supplementary Appendix. Only stat-
isticians who were responsible for preparing the 
reports for the independent data and safety moni-
toring committee and essential manufacturing and 
distribution staff members had access to the list 
of identifiers matched to the intervention.
Study Procedures
After initial screening and baseline visits, patients 
were scheduled for eight weekly visits, which 
were followed by eight visits until 18 months af-
ter randomization (Fig. S1 in the Supplementary 
Appendix). All patients underwent a baseline clin-
ical examination that included posteroanterior 
chest radiography, pregnancy testing if relevant, 
collection of two sputum specimens for micro-
biologic examination, physical examination, tests 
of visual acuity (Ishihara and Snellen), and uri-
nalysis. Safety monitoring — which included test-
ing of hepatic function (aspartate aminotransfer-
ase, alanine aminotransferase, and bilirubin), 
vitamin K, prothrombin time, partial thrombo-
plastin time, blood count (hemoglobin and plate-
let count), urea, electrolytes, and creatinine — was 
performed at screening and at weeks 2, 8, 12, 
and 17, with additional liver-function testing at 
week 4.
Sputum was decontaminated with acetylcys-
teine–sodium hydroxide, examined microscopi-
cally, and cultured on Lowenstein–Jensen solid 
medium and in liquid medium in a Mycobacteria 
Growth Indicator Tube (MGIT) (Becton Dickin-
son). All analyses were performed according to 
the REMoxTB laboratory and quality manuals 
(available on request). We performed mycobacte-
rial speciation using the AccuProbe assay (Gen-
Probe), and determined the susceptibility of strains 
to streptomycin, isoniazid, rifampin, and pyrazin-
amide using the MGIT manufacturer’s instruc-
tions. We tested the susceptibility to moxifloxa-
cin using a breakpoint of 0.125 mg per liter. In 
countries with a high rate of multidrug-resistant 
tuberculosis or quinolone resistance (>5%), initial 
sputum samples were tested for rifampin resis-
tance with the use of the GenoType MTBDRplus 
assay and GenoType MTBDRsl assay, respectively 
(Hain Lifescience). We used 24-locus mycobacte-
rial-interspersed-repetitive-unit (MIRU) analysis 
to compare the initial strains with the recurrence 
strains.17
Study Outcomes
The primary efficacy outcome was the propor-
tion of patients who had bacteriologically or clini-
cally defined failure or relapse within 18 months 
after randomization (a composite unfavorable 
outcome). Culture-negative status was defined as 
two negative-culture results at different visits 
without an intervening positive result. The date 
of culture-negative status was defined as the date 
of the first negative-culture result. This status 
continued until there were two positive cultures, 
without an intervening negative culture, or until 
there was a single positive culture that was not 
followed by two negative cultures. Relapse strains 
were those shown to be identical on 24-locus 
MIRU analysis.
The primary safety outcome was the propor-
tion of patients with grade 3 or 4 adverse events 
that were graded according to a modified version 
of the toxicity criteria of the Division of AIDS of 
the National Institute of Allergy and Infectious 
Diseases.
Statistical Analysis
We determined that a sample size of 633 patients 
per group would provide a power of 85% to show 
noninferiority of the two moxifloxacin interven-
tions to the control regimen with a margin of 
6 percentage points, assuming a one-sided type I 
error of 0.0125 (Bonferroni correction). We esti-
mated that 10% of the patients in each study group 
would have a unfavorable outcome and that 15% 
would have outcomes that could not be evaluat-
ed. (All definitions are provided in the Supple-
mentary Appendix.) This margin of 6 percentage 
points reflected consultation with clinicians in 
high-burden countries and reanalysis of previous 
trials showing the effect of shortening treatment 
to 4 months without substituting a new drug.
Noninferiority was defined as a between-group 
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difference of less than 6 percentage points in the 
upper boundary of the two-sided 97.5% Wald con-
fidence interval for the proportion of patients with 
an unfavorable outcome. We used a generalized 
linear model with identity-link function with ad-
justment for stratification variables (weight group 
and study center). We performed both modified 
intention-to-treat and per-protocol analyses, with 
the latter considered to be the primary analysis. 
In the modified intention-to-treat analysis, we 
excluded patients with resistance to moxifloxa-
cin or rifampin at baseline and those in whom 
the outcome could not be assessed (e.g., patients 
who had reinfection). (Detailed definitions are 
provided in Section 2 in the Supplementary Ap-
pendix.) We also performed a number of sensi-
tivity and secondary analyses of the primary out-
come to test the robustness of the results (Tables 
S3A and S3B in the Supplementary Appendix).
We used the chi-square test to compare the 
patients’ sputum-culture status at the end of 
8 weeks (intensive phase) across treatment groups 
and the log-rank test to compare the time to 
culture-negative status. We used similar methods 
to analyze other secondary outcomes, including 
the time to an unfavorable outcome, the status 
at the end of treatment, the status at 12 and 18 
months among patients with a favorable outcome 
at end of treatment, and the status at 18 months 
according to a blinded clinical review of the data.
All patients who received at least one dose of 
a study medication were included in the safety 
analysis. The proportions of patients who had at 
least one grade 3 or 4 adverse event were com-
pared across treatment groups with the use of the 
chi-square test.
R esult s
Study Patients
A total of 2763 patients were screened and 1931 
underwent randomization: 909 in South Africa, 
376 in India, 212 in Tanzania, 136 in Kenya, 119 
in Thailand, 69 in Malaysia, 66 in Zambia, 22 in 
China, and 22 in Mexico (Table S4 in the Supple-
mentary Appendix). The principal reasons for 
ineligibility were a lack of confirmation of smear 
positivity in the study laboratory, a CD4+ count 
of less than 250 cells per cubic millimeter, or 
multidrug-resistant disease, as detected by means 
of the Hain test (Fig. 1). The demographic and 
clinical characteristics of the patients were simi-
lar in the three study groups (Table 1, and Tables 
S5 and S6 in the Supplementary Appendix).
The most common reason that patients were 
excluded from the modified intention-to-treat 
analysis was that they were found to be ineligible 
on the basis of data that were collected before 
randomization (e.g., lack of confirmation of the 
diagnosis of tuberculosis or confirmed multidrug-
resistant tuberculosis). The most common reasons 
for exclusion from the per-protocol analysis were 
a change of treatment for reasons other than 
treatment failure and a loss to follow-up (Fig. 1). 
Of the 1931 patients who underwent randomiza-
tion, 89% in the isoniazid group, 92% in the 
ethambutol group, and 89% in the control group 
met the requirements for treatment adherence, 
which was based on receipt of approximately 80% 
of the assigned regimen (see the Supplementary 
Appendix for details).
Primary Outcome
In the per-protocol analysis, a favorable outcome 
was reported in 436 patients (85%) in the isonia-
zid group, as compared with 467 patients (92%) 
in the control group, for an adjusted absolute dif-
ference of 6.1 percentage points (97.5% confidence 
interval [CI], 1.7 to 10.5) favoring the control 
group (Table 2, and Fig. S2 in the Supplementary 
Appendix). A favorable outcome was reported in 
419 patients (80%) in the ethambutol group, for 
an adjusted absolute difference of 11.4 percent-
age points (97.5% CI, 6.7 to 16.1), as compared 
with the control group.
In the modified intention-to-treat analysis, the 
corresponding values also favored the control 
group, with a favorable outcome reported in 436 
patients (77%) in the isoniazid group, as com-
pared with 468 (84%) in the control group, for 
an adjusted absolute difference of 7.8 percentage 
points (97.5% CI, 2.7 to 13.0), and in 419 patients 
(76%) in the ethambutol group, for an adjusted 
absolute difference of 9.0 percentage points 
(97.5% CI, 3.8 to 14.2) (Table 2, and Fig. S2 in the 
Supplementary Appendix). Results of all sensitiv-
ity analyses were consistent with those in the per-
protocol and modified intention-to-treat analy-
ses (Table S3A in the Supplementary Appendix).
The most common reason for an unfavorable 
outcome was relapse after conversion to culture-
negative status after the end of active treatment 
(in 46 patients in the isoniazid group, 64 in the 
ethambutol group, and 12 patients in the control 
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group). A similar pattern of results was seen in the 
modified intention-to-treat analysis (Table 2). There 
were no unequivocal cases of acquired resistance, 
but there were four cases of possible resistance 
— one in the ethambutol group (for moxifloxacin) 
and three in the control group (two for rifampin 
and one for isoniazid) — which require future 
whole-genome sequencing for interpretation.
Subgroup Analyses
There was no evidence that between-group dif-
ferences in the primary outcome varied accord-
ing to HIV status, region, recruitment site, age 
group, isoniazid susceptibility, or cavitation. The 
proportion of unfavorable outcomes among fe-
male patients, as compared with male patients, 
was similar in the three study groups (test of in-
1931 Underwent randomization
2763 Patients were screened
832 Had screening failure
290 Did not have positive smear
196 Had CD4+ count <250/mm3
116 Had initial isolate MDR
230 Had other reason
110 Had late-screening failure
61 Had MDR
20 Had protocol violation
29 Did not have confirmed
 tuberculosis
640 Were assigned to control group 636 Were assigned to ethambutol group
568 Were included in modified intention-
to-treat analysis
551 Were included in modified intention-
to-treat analysis
85 Were excluded
40 Had late-screening
failures
11 Were excluded
during treatment
10 Had reinfections
24 Were excluded
during follow-up
phase
87 Were excluded
38 Had late-screening
failures
12 Were excluded
during treatment
13 Had reinfections
24 Were excluded
during follow-up
phase
85 Were excluded
32 Had late-screening
failures
18 Were excluded
during treatment
19 Had reinfections
16 Were excluded
during follow-up
phase
555 Were included in modified intention-
to-treat analysis
514 Were included in per-protocol
analysis
524 Were included in per-protocol
analysis
45 Were excluded
30 Changed treatment
(not failure)
13 Were lost to follow-
up before 6 mo
2 Had additional
major protocol
violations
54 Were excluded
42 Changed treatment
(not failure)
10 Were lost to follow-
up before 6 mo
2 Had inadequate
treatment
27 Were excluded
21 Changed treatment
(not failure)
6 Were lost to follow-
up before 6 mo
510 Were included in per-protocol
analysis
655 Were assigned to isoniazid group
Figure 1. Enrollment and Outcomes.
MDR denotes multidrug resistance.
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Table 1. Baseline Characteristics of Patients in the Per-Protocol Population.*
Characteristic
Control 
Group
(N = 510)
Isoniazid 
Group
(N = 514)
Ethambutol 
Group
(N = 524)
All Patients
(N = 1548)
number of patients (percent)
Male sex 356 (70) 351 (68) 369 (70) 1076 (70)
Weight group†
<40 kg 50 (10) 44 (9) 58 (11) 152 (10)
40–45 kg 80 (16) 90 (18) 82 (16) 252 (16)
>45–55 kg 206 (40) 210 (41) 204 (39) 620 (40)
>55–75 kg 161 (32) 158 (31) 174 (33) 493 (32)
>75 kg 13 (3) 12 (2) 6 (1) 31 (2)
Age group
<25 yr 160 (31) 162 (32) 146 (28) 468 (30)
25–35 yr 145 (28) 162 (32) 175 (33) 482 (31)
>35 yr 205 (40) 190 (37) 203 (39) 598 (39)
Race or ethnic group‡
Black 238 (47) 210 (41) 237 (45) 685 (44)
Asian 160 (31) 154 (30) 161 (31) 475 (31)
Mixed race 111 (22) 148 (29) 126 (24) 385 (25)
Other 1 (<1) 2 (<1) 0 3 (<1)
Smoking status
Never 246 (48) 231 (45) 230 (44) 707 (46)
Past 119 (23) 111 (22) 134 (26) 364 (24)
Current 145 (28) 172 (33) 160 (31) 477 (31)
HIV positivity§ 38 (7) 37 (7) 35 (7) 110 (7)
Drug resistance¶
Isoniazid 29 (6) 34 (7) 39 (7) 102 (7)
Pyrazinamide 14 (3) 7 (1) 6 (1) 27 (2)
Cavitation‖ 368 (72) 357 (69) 367 (70) 1092 (71)
Time to positivity on MGIT sputum culture
≥5 days 266 (52) 263 (51) 258 (49) 787 (51)
<5 days 229 (45) 239 (46) 254 (48) 722 (47)
Not available 15 (3) 12 (2) 12 (2) 39 (3)
* There were no significant differences between the study groups. HIV denotes human immunodeficiency virus, and 
MGIT Mycobacteria Growth Indicator Tube.
† The median body-mass index (the weight in kilograms divided by the square of the height in meters) was 18.4 (range, 
12.1 to 50.9) in the control group, 18.3 (range, 12.0 to 33.1) in the isoniazid group, 18.4 (range, 12.2 to 32.6) in the eth-
ambutol group, and 18.3 (range, 12.0 to 50.9) for all patients.
‡ Race or ethnic group was reported by the investigator. Asian category included both South Asians and East Asians.
§ A single patient had missing HIV status.
¶ Resistance results were missing for isoniazid in 24 patients and for pyrazinamide in 27 patients.
‖ Cavitation status was missing for 148 patients.
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Table 2. Primary Efficacy Analysis in Per-Protocol and Modified Intention-to-Treat Populations.*
Variable Per-Protocol Analysis Modified Intention-to-Treat Analysis
Control 
Group
(N = 510)
Isoniazid 
Group
(N = 514)
Ethambutol 
Group
(N = 524)
All  
Patients
(N = 1548)
Control 
Group
(N = 555)
Isoniazid 
Group
(N = 568)
Ethambutol 
Group
(N = 551)
All  
Patients
(N = 1674)
Favorable outcome — no. (%)
Patients with outcome 467 (92) 436 (85) 419 (80) 1322 (85) 468 (84) 436 (77) 419 (76) 1323 (79)
Culture-negative status at 18 mo 409 (80) 389 (76) 367 (70) 1165 (75) 410 (74) 389 (68) 367 (67) 1166 (70)
Unable to produce sputum 0 2 (<1) 0 2 (<1) 0 2 (<1) 0 2 (<1)
Unable to produce sputum at  
18 mo but culture-
negative status earlier
49 (10) 31 (6) 35 (7) 115 (7) 49 (9) 31 (5) 35 (6) 115 (7)
Missing data on L–J culture at  
18 mo and MGIT 
negative
9 (2) 14 (3) 17 (3) 40 (3) 9 (2) 14 (2) 17 (3) 40 (2)
Unfavorable outcome — no. (%)†
Patients with outcome 43 (8) 78 (15) 105 (20) 226 (15) 87 (16) 132 (23) 132 (24) 351 (21)
6-Mo treatment phase
Nonviolent death 5 (1) 6 (1) 7 (1) 18 (1) 5 (1) 6 (1) 7 (1) 18 (1)
Treatment failure‡
Culture-confirmed 3 (1) 4 (1) 1 (<1) 8 (1) 3 (1) 4 (1) 1 (<1) 8 (<1)
Not culture-confirmed 4 (1) 1 (<1) 4 (1) 9 (1) 4 (1) 1 (<1) 4 (1) 9 (1)
Adverse reaction NA NA NA NA 18 (3) 15 (3) 9 (2) 42 (3)
Withdrawal of consent NA NA NA NA 8 (1) 18 (3) 8 (1) 34 (2)
Relocation NA NA NA NA 2 (<1) 4 (1) 4 (1) 10 (1)
Other investigator decision NA NA NA NA 2 (<1) 5 (1) 0 7 (<1)
No completion of treatment NA NA NA NA 13 (2) 10 (2) 6 (1) 29 (2)
Follow-up
Relapse after culture-negative 
status
12 (2) 46 (9) 64 (12) 122 (8) 13 (2) 46 (8) 64 (12) 123 (7)
Retreated for tuberculosis 14 (3) 17 (3) 27 (5) 58 (4) 14 (3) 18 (3) 27 (5) 59 (4)
Death from tuberculosis or 
respiratory distress
2 (<1) 0 0 2 (<1) 2 (<1) 0 0 2 (<1)
No culture-negative status
Ever 1 (<1) 1 (<1) 0 2 (<1) 1 (<1) 2 (<1) 0 3 (<1)
At last visit 2 (<1) 3 (1) 2 (<1) 7 (<1) 2 (<1) 3 (1) 2 (<1) 7 (<1)
Adjusted difference from control 
in rate of unfavorable 
outcome — percent-
age points (97.5% CI)
NA 6.1  
(1.7–10.5)
11.4 
(6.7–16.1)
NA NA 7.8
(2.7–13.0)
9.0  
(3.8–14.2)
NA
* The treatment phase was defined as any time from randomization to 32 weeks after randomization (26 weeks plus 6-week window). L–J de-
notes Lowenstein–Jensen solid medium, and NA not applicable.
† During follow-up, the relapse and retreatment categories include patients during the scheduled end of active treatment (after month 4 for 
the moxifloxacin-containing groups and month 6 for the control group). In the per-protocol analysis, data from 24-locus mycobacterial-inter-
spersed-repetitive-unit analysis were missing for 9 of 17 patients with treatment failure, 42 of 122 patients with relapse, and 38 of 58 pa-
tients who were retreated for tuberculosis.
‡ Listed are patients who were receiving active treatment in whom treatment failed.
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teraction, P = 0.004 for the isoniazid group and 
P = 0.02 for the ethambutol group) (Table S3B in 
the Supplementary Appendix).
Time to Negative-Culture Status
In Kaplan–Meier analyses, patients in the isonia-
zid group and the ethambutol group had conver-
sion to culture-negative status sooner than those 
in the control group in sputum analyses with the 
use of Lowenstein–Jensen solid medium (Fig. 2B) 
and MGIT medium (Fig. S3 and Table S7 in the 
Supplementary Appendix) (P<0.01 for both analy-
ses). More patients receiving the moxifloxacin-
containing regimens had culture-negative status 
at 8 weeks, but the difference was not significant 
(Table S8 in the Supplementary Appendix).
Time to an Unfavorable Outcome
In the per-protocol analyses, the time to an unfa-
vorable outcome was shorter in the isoniazid group 
than in the control group (hazard ratio, 1.87; 
97.5% CI, 1.07 to 2.67) and was further reduced 
in the ethambutol group (hazard ratio, 2.56; 
97.5% CI, 1.51 to 3.60) (Fig. 2A, and Table S9 in 
the Supplementary Appendix).
Adverse Events
There were no significant between-group differ-
ences in the incidence of grade 3 or 4 adverse 
events, with reports of events in 127 patients (19%) 
in the isoniazid group and 111 patients (17%) in 
the ethambutol group, as compared with 123 pa-
tients (19%) in the control group (Table 3). A to-
tal of 349 serious adverse events occurred in 173 
patients, with 246 events occurring during the 
treatment period and 103 during follow-up. There 
were 43 deaths (16 during the treatment period 
and 27 during follow-up) during the study, 30 of 
which were deemed to be tuberculosis-related 
(Table S10 in the Supplementary Appendix). Over-
all, the numbers of serious adverse events, types 
of events, and numbers of patients with events 
(including the number of deaths) were similar in 
the three study groups during both the treatment 
period and the follow-up period.
There were no significant between-group dif-
ferences in the incidence of adverse events of 
special interest, including tendinopathy, seizure, 
clinically significant cardiac toxicity, hypoglyce-
mia or hyperglycemia, and peripheral neuropathy. 
The proportions of events were similar in the 
study groups when all adverse events were con-
sidered. There were no significant differences in 
any measures of biochemical, hematologic, or 
hepatic safety.
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Figure 2. Kaplan–Meier Estimates of the Time to an Unfavorable Outcome 
and Conversion to Culture-Negative Status.
Panel A shows that the time until patients had an unfavorable outcome was 
shorter in the isoniazid group than in the control group (hazard ratio, 1.25 
[97.5% CI, 1.08 to 1.42]) and was further reduced in the ethambutol group 
(hazard ratio, 1.21 [97.5% CI, 1.05 to 1.37]). Panel B shows the time until 
conversion to culture-negative status, which occurred sooner in the isonia-
zid group and the ethambutol group than in the control group, according to 
analyses of sputum samples cultured in Lowenstein–Jensen solid medium. 
Patients who were excluded from the primary per-protocol analysis were in-
cluded in this analysis, but data were censored at the time of exclusion 
from the per-protocol analysis.
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Discussion
In this phase 3 trial, we aimed to determine 
whether the promising data that were observed 
for moxifloxacin in studies in animals and phase 
2 studies translated into an effective reduction in 
the duration of the standard tuberculosis treat-
ment regimen. The trial showed that the substi-
tution of moxifloxacin in 4-month regimens based 
on either isoniazid or ethambutol did not meet 
the margin for noninferiority, as compared with 
the 6-month control regimen. The same conclu-
sions were reached when the outcome was deter-
mined with the use of MGIT cultures of sputum 
samples. Among patients receiving the two moxi-
floxacin-containing regimens, a small number 
had treatment failures, but a larger number had 
a relapse after the end of active treatment. The 
difference between the isoniazid group and the 
ethambutol group may be due to the bactericidal 
effect of isoniazid or the presence of three drugs 
over a 4-month period. The similarity in outcome 
among women in the isoniazid group and the 
control group may represent a chance finding 
but merits further investigation.
It has been previously suggested that Asian 
patients often have a more chronic form of tu-
berculosis with a different clinical course than 
that in African patients,18,19 but we did not see 
any evidence of variation in clinical-disease out-
come in the different racial groups. Our ap-
proach in the conduct of this trial, including 
standardized laboratory methods and clinical 
management, has resulted in consistent results 
across more than 20 sensitivity analyses, with 
minimal variation among study centers on dif-
ferent continents.
In comparison with other trials that used 
fluoroquinolones in a 4-month regimen, the rates 
of an unfavorable outcome in the experimental 
groups in our study are lower than those in the 
RIFAQUIN regimen20 and similar to those found 
Table 3. Safety Analysis.*
Adverse Event
Control Group
(N = 639)
Isoniazid Group
(N = 655)
Ethambutol Group
(N = 636)
All Patients
(N = 1930)
number of patients (percent)
During treatment phase  
or follow-up
Any 123 (19) 127 (19) 111 (17) 361 (19)
Grade 3 only 83 (13) 90 (14) 82 (13) 255 (13)
Grade 4 40 (6) 37 (6) 29 (5) 106 (5)
Serious adverse event 59 (9) 62 (9) 52 (8) 173 (9)
Death
Any 16 (3) 15 (2) 12 (2) 43 (2)
Tuberculosis-related 11 (2) 10 (2) 9 (1) 30 (2)
During treatment phase only
Any 111 (17) 105 (16) 99 (16) 315 (16)
Grade 3 only 76 (12) 71 (11) 73 (11) 220 (11)
Grade 4 35 (5) 34 (5) 26 (4) 95 (5)
Serious adverse event 46 (7) 40 (6) 35 (6) 121 (6)
Death
Any 5 (1) 6 (1) 5 (1) 16 (1)
Tuberculosis-related 4 (1) 6 (1) 5 (1) 15 (1)
* Listed are all patients who had at least one grade 3 or 4 adverse event. The safety population includes all patients who 
underwent randomization and who received at least one dose of a study drug. One patient who underwent randomiza-
tion but did not receive a study drug was excluded from the safety analysis. A detailed list of serious adverse events is 
provided in Table S10 in the Supplementary Appendix.
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in the OFLOTUB trial.21 In trials evaluating 
4-month streptomycin-containing regimens that 
were performed in the 1970s in East Africa and 
Singapore, rates of relapse ranged from 11 to 40% 
after 2 years of follow-up.18,19
In our study, a daily regimen of moxifloxacin 
in combination with standard antituberculosis 
agents for 4 months had an acceptable side-effect 
profile. We did not find any evidence of either 
hypoglycemia or hyperglycemia or tendinopathies 
that have been associated with fluoroquino-
lones,22,23 nor did we find evidence of increased 
hepatic dysfunction, a potential concern in regi-
mens containing moxifloxacin or lacking isonia-
zid.24 There was no clinical evidence of cardiac 
toxicity, although electrocardiography was not 
performed systematically. These are important 
findings for future regimens that may use moxi-
floxacin in combination with other agents in tu-
berculosis treatment.25
Our findings raise questions about progres-
sion decisions throughout the development path-
way for tuberculosis drugs. Data from studies in 
mice predicted that the inclusion of moxifloxa-
cin would result in a reduction of 1 to 2 months 
in the treatment duration, as compared with stan-
dard therapy.12,13 In our study of such treatment 
shortening, the moxifloxacin-containing regimens 
did not work adequately, suggesting that the mu-
rine model may have overpredicted the sterilizing 
potency of moxifloxacin in this regimen.
More important is the observed poor predict-
ability of culture conversion for long-term out-
comes. Although 2-month culture conversion is 
associated with relapse-free cure, this observed 
correlation in populations is not strong enough to 
reliably predict outcomes for individual patients or 
definitively guide the selection of regimen in drug 
development.26,27 This finding underlines the im-
portance of the content and duration of treatment 
in the following weeks.28 Four 2-month studies 
of the inclusion of moxifloxacin in the standard 
regimen have been reported, with variable re-
sults.14-16,29 The only study to report a hazard 
ratio for the time to culture conversion was that 
of Rustomjee et al.,14 who, in a study involving 
approximately 50 patients per group, found that 
the hazard ratio for the time to culture conver-
sion for the moxifloxacin-containing regimen, as 
compared with the standard regimen, was 1.73, 
indicating a shorter duration. This raised the pos-
sibility that a 4-month regimen might be effec-
tive, although the 95% confidence interval ranged 
from 1.15 to 2.60. In our study, with more than 
600 patients in each group, we found a more 
precise estimate of the hazard ratio to be 1.25 
(95% CI, 1.10 to 1.40), a result that is within the 
confidence interval found previously14 but with a 
smaller effect, which would seem unlikely to 
merit progression to a phase 3 trial. Thus, such 
short trials may correlate with long-term out-
comes, but the small sample size and resulting 
wide confidence intervals limit their ability to 
predict treatment shortening.
This limitation suggests that efficient drug 
development for tuberculosis may require a dif-
ferent approach. Instead of relying on the results 
of 2-month phase 2 trials to select candidate regi-
mens for phase 3 studies, investigators might find 
that the most efficient approach is to conduct 
phase 3 trials as quickly as possible while estab-
lishing more feasible and less costly approaches 
to performing these studies. Possible improve-
ments could include larger noninferiority margins, 
permitting smaller sample sizes, and building 
multiple treatment durations into each study.
In conclusion, in patients with uncomplicated, 
smear-positive tuberculosis, the noninferiority of 
the moxifloxacin-containing regimens was not 
shown, despite the fact that these regimens had 
better bactericidal activity than the standard con-
trol regimen.30
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